Literature DB >> 1280073

Treatment of severe thrombocytopenia in systemic lupus erythematosus with intravenous gammaglobulin.

E J ter Borg1, C G Kallenberg.   

Abstract

Three patients with lupus with severe auto-immune thrombocytopenia were treated with high doses of intravenous gammaglobulin. In the patient with active disease a prolonged but partial response with respect to platelet counts was observed. In the two other patients who had no disease activity other than thrombocytopenia at the time of intravenous gammaglobulin treatment a minor (and only transient) increase in platelet counts was seen after treatment. No change in the state of disease activity nor in the levels of antinuclear antibodies, circulating immune complexes, nor complement C3/4 was observed in these three patients after treatment with intravenous gammaglobulin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1280073      PMCID: PMC1012421          DOI: 10.1136/ard.51.10.1149

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  13 in total

1.  In vivo reduction of circulating C1q binding immune complexes by intravenous gammaglobulin administration.

Authors:  R Y Lin; S P Racis
Journal:  Int Arch Allergy Appl Immunol       Date:  1986

2.  Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura.

Authors:  J F Delfraissy; G Tchernia; Y Laurian; C Wallon; P Galanaud; J Dormont
Journal:  Br J Haematol       Date:  1985-06       Impact factor: 6.998

3.  Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia.

Authors:  W P Maier; D S Gordon; R F Howard; M N Saleh; S B Miller; J D Lieberman; P M Woodlee
Journal:  Arthritis Rheum       Date:  1990-08

4.  Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus.

Authors:  M M Frank; M I Hamburger; T J Lawley; R P Kimberly; P H Plotz
Journal:  N Engl J Med       Date:  1979-03-08       Impact factor: 91.245

5.  Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin.

Authors:  J Fehr; V Hofmann; U Kappeler
Journal:  N Engl J Med       Date:  1982-05-27       Impact factor: 91.245

6.  High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood.

Authors:  P Imbach; S Barandun; V d'Apuzzo; C Baumgartner; A Hirt; A Morell; E Rossi; M Schöni; M Vest; H P Wagner
Journal:  Lancet       Date:  1981-06-06       Impact factor: 79.321

7.  Successful treatment of refractory systemic lupus erythematosus with intravenous immunoglobulins.

Authors:  K Akashi; K Nagasawa; T Mayumi; E Yokota; N Oochi; T Kusaba
Journal:  J Rheumatol       Date:  1990-03       Impact factor: 4.666

Review 8.  The use and mechanism of action of intravenous immunoglobulin in the treatment of immune haematologic disease.

Authors:  J B Bussel; M W Hilgartner
Journal:  Br J Haematol       Date:  1984-01       Impact factor: 6.998

9.  High dose intravenous IgG reduces platelet associated immunoglobulins and complement in idiopathic thrombocytopenic purpura.

Authors:  J Winiarski; A Kreuger; J Ejderhamn; G Holm
Journal:  Scand J Haematol       Date:  1983-10

10.  Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin.

Authors:  D Y Leung; J C Burns; J W Newburger; R S Geha
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

View more
  3 in total

Review 1.  Lupus therapy.

Authors:  H Baart de la Faille
Journal:  Clin Investig       Date:  1994-10

Review 2.  Haematological manifestations of lupus.

Authors:  Anum Fayyaz; Ann Igoe; Biji T Kurien; Debashish Danda; Judith A James; Haraldine A Stafford; R Hal Scofield
Journal:  Lupus Sci Med       Date:  2015-03-03

3.  Thrombocytopenia in Systemic Lupus Erythematosus: Clinical Manifestations, Treatment, and Prognosis in 230 Patients.

Authors:  Jin-Hee Jung; Moon-Seung Soh; Young-Hwan Ahn; Yoo-Jin Um; Ju-Yang Jung; Chang-Hee Suh; Hyoun-Ah Kim
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.